HYFTOR® (sirolimus topical gel) 0.2% is an mTOR inhibitor in a clear gel.
HYFTOR® is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients 6 years of age and older. Facial angiofibroma is one of the most visible manifestations of TSC.1,2
CONTRAINDICATIONS
HYFTOR® is contraindicated in patients with a history of hypersensitivity to sirolimus or any other component of HYFTOR®.
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most common adverse reactions (≥1%) are dry skin, application site irritation, pruritus, acne, acneiform dermatitis, ocular hyperemia, skin hemorrhage, and skin irritation.
USE IN SPECIFIC POPULATIONS
Please see full Prescribing Information for additional safety information.
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
This site is intended for U.S. healthcare professionals only.
HYFTOR® is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.
CONTRAINDICATIONS
HYFTOR® is contraindicated in patients with a history of hypersensitivity to sirolimus or any other component of HYFTOR®.
By submitting your email address, you are opting in and may be provided with online advertisements or communications on Nobelpharma or third-party websites that are tailored to you, for example, on the basis of nonidentifying information or of your web browsing activity. When a Nobelpharma communication is delivered to you, you will see information about how to opt-out. By clicking the arrow, you agree and understand that your information will be governed by our Privacy Policy.
Link pending once FDA approval comes in…